Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS 2: Oral semaglutide 50 mg once daily in East Asian adults with overweight or obesity
jRCT2011210053Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 2 more comparing Oral semaglutide 50 mg once daily with Placebo once daily (2 arms). Primary endpoints: Relative change in body weight from baseline to end-of-treatment and Proportion of participants achieving ≥5% body weight reduction at end-of-treatment. Started Nov 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)lipid disorder
Beyond the preview
Go deeper on jRCT2011210053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210053.